Status:
Ready to upload
Record number:
2190
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
(Council of Europe, 2018): Potential donors with pilocytic astrocytoma (WHO grade I) may be considered for organ donation with minimal risk of transmission.
Extra-neural metastases from low grade astrocytomas (WHO grade II) are rare, and have been associated with resection and ventriculo-peritoneal shunts. In the absence of these risk factors the donor may be considered minimal risk. Risk may increase with the extent of performed interventions.
A complete histological examination of the tumour should be performed so that areas of more aggressive malignancy are ruled out. Since astrocytomas have a tendency to relapse with a histologically higher grade of malignancy, new histological examinations should be performed where relapse occurs to regrade the tumour.
If the tumor co-exists with histological areas of greater malignancy or is very invasive locally, it should be considered high grade and will be associated with an increased risk of transmission.
Spontaneous extra-neural metastases of anaplastic astrocytomas and glioblastoma multiforme are rare, but have been observed, and occur more frequently when associated with prior surgical treatment and/or ventriculo-peritoneal drainage, or chemo-/radiotherapy.
Potential donors with anaplastic astrocytomas (WHO grade III) can be accepted as organ donors. Transmission risk is considered low to intermediate for tumours without any risk factors.
Potential donors with glioblastoma multiforme (WHO grade IV) are considered intermediate to high risk for transmission depending on the different national recommendations, which are expected to be adjusted with increasing evidence.
The transmission risk is increased (high risk) in all cases with previous interventions such as tumour resection, ventriculo-peritoneal/-atrial drainage and/or cranial chemo-/radiotherapy.
Time to detection:
This study adds to the cases with good outcome after realizing donors with primary CNS malignancy. The authors mention the UK data, where the risk for transmission is 1.5% in overall and in WHO Grad IV 2.2% and increases with various means of intervention and treatment furhter. In conclusion of all known data realizing donors with primary CNS malignancy is possible with proper evaluation as well as cautious consideration of the risks associated.
Alerting signals, symptoms, evidence of occurrence:
none
Demonstration of imputability or root cause:
none
Groups audience:
Keywords:
Suggest new keywords:
Malignancy
Single Center Series
Deceased donor
liver transplant
liver recipient
Astrocytoma/glioblastoma multiform E. (WHO grade 4)
Medulloblastoma (WHO grade 4)
CNS lymphoma
Therapy not discussed
Suggest references:
Ince V, Ersan V, Ozdemir F, Barut B, Koc C, Isik B, Kayaalp C, Yilmaz S. Deceased donor liver transplantation from donors with central nervous system malignancy: Experience of the Inonu University. North Clin Istanb. 2017 Oct 25;4(3):213-217. doi: 10.14744/nci.2017.74436. PMID: 29270568; PMCID: PMC5724914.
Note:
upload MN 5/8/22
first review startetd CLFF 5/19/22
second review AE 24/6/2024
Expert comments for publication:
This single center study shows again, that donors with primary CNS Malignancies can be used when the they are evaluated properly and the risks are well considered despite the results of their own study. The single case with CNS-Lmyphoma needs further evaluation before any conclusion becomes possible (conflicitng result of no transmission versus other cases in the literature).